Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Fallopian Tube Neoplasms 7Ovarian Neoplasms 6Breast Neoplasms 4Multiple Myeloma 3Lymphoma 3Sarcoma, Kaposi 2Neoplasms 2Multi-centric Castleman's Disease 2Leukemia 2Hodgkin Disease 2Triple Negative Breast Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lymphadenopathy 1

Interventions

Cyclophosphamide 10fludarabine 7trametinib 6Specimen Handling 6Mycophenolic Acid 6Whole-Body Irradiation 5Sirolimus 5Nivolumab 5Biopsy 5fludarabine phosphate 4Magnetic Resonance Spectroscopy 4dabrafenib 3Prednisone 3Melphalan 3Ipilimumab 3GSK2636771 3Filgrastim 3Electrocardiography 3Crizotinib 3CTLA-4 Antigen 3Busulfan 3palbociclib 2osimertinib 2keyhole-limpet hemocyanin 2capivasertib 2binimetinib 2adavosertib 2X-Rays 2Mesna 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hematologic Neoplasms × liposomal doxorubicin × Clear all
NCT00051311 2021-09-09

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
62 enrolled 15 charts
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡